Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952460 | 1.00 | ERN1 (0.55) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL29957088 | 0.84 | TRIM24 (0.57) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL8696330 | 0.84 | TRIM24 (0.57) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL518510 | 0.78 | TUBB4A (0.59) | ALDH1A1MEN1GAAMAPTTHRB | |
| SCHEMBL1960037 | 0.78 | ENPP2 (0.50) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL29385414 | 0.78 | TUBB4A (0.59) | ALDH1A1MEN1GAAMAPTTHRB | |
| SCHEMBL4145654 | 0.78 | NQO1 (0.48) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL645367 | 0.77 | ENPP2 (0.48) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL9935773 | 0.77 | ENPP2 (0.48) | ERN1ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL3789771 | 0.77 | ALDH1A1 (0.53) | ERN1ALDH1A1KDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | claimed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021147882-A1 | DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-3274335-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150971-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-09-29 | — | — | WO | disclosed |
| US-6541490-B1 | Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt | EUKARION, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1119573-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6177419-B1 | ANTIOXIDANT CHELATE COMPOUNDS FOR PREVENTING OXYGEN FREE RADICAL-ASSOCIATED DISEASES IN MAMMALS; NEUROPROTECTANTS, SUPEROXIDE DISMUTASE (SOD), CATALASE (CAT) AND/OR PEROXIDASE (POD) MIMETICS | EUKARION, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000009512-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, SCN1A, SCN3A | ERN1 3357/4885ALDH1A1 1962/4885KDM4E 2079/4885 |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | SCN1B, SCN1A, SCN3A | ERN1 3330/4885ALDH1A1 1874/4885KDM4E 1956/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ERN1 1817/4885ALDH1A1 2352/4885KDM4E 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.